Tryton launches branched stent in EU
This article was originally published in Clinica
Executive Summary
Tryton Medical has launched its novel Side Branch Stent System onto the European market. Intended to treat atherosclerotic lesions at the site of a bifurcation, the cobalt chromium stent is designed to be implanted along with a conventional drug-eluting stent. The system is now on sale in the Netherlands, where it will be distributed by TOP Medical (Nuth, the Netherlands). Further European launches will follow in the coming months. The Research Triangle Park, North Carolina-based firm will also start a study evaluating the device in real-life practice "in the coming weeks." Around 20% of patients treated for coronary artery disease are treated for bifurcated lesions. The stent was CE marked in February (see Clinica No 1293, p 26); it is not approved in the US.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.